<SEC-DOCUMENT>0001213900-24-046313.txt : 20240523
<SEC-HEADER>0001213900-24-046313.hdr.sgml : 20240523
<ACCEPTANCE-DATETIME>20240523170015
ACCESSION NUMBER:		0001213900-24-046313
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240523
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240523
DATE AS OF CHANGE:		20240523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		24979388

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0206715-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ABVC="http://abvcpharma.com/20240522">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_ABVC_abvcpharma.com_20240522 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20240523_20240523 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000004" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20240522.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-05-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-23</xbrli:startDate>
        <xbrli:endDate>2024-05-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20240523__20240523_zKI7ECEVa3N9"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_909_edei--DocumentPeriodEndDate_c20240523__20240523_zRsbOhJW3Gr4"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 23, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20240523__20240523_zHsXDnalPry9"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000011" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20240523__20240523_zaxALDCAgpNh"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20240523__20240523_zKFO98YaZ0Jf"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000013" name="dei:EntityFileNumber">001-40700</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20240523__20240523_z722YWkYiFI9"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20240523__20240523_zQx9HR3H59ba"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000015" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240523__20240523_zg2QbMbs02q"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000016" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20240523__20240523_zCIGH4nmEJMc"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000017" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20240523__20240523_zP3MPjFTCm0k"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000018" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_905_edei--CityAreaCode_c20240523__20240523_zTkwTVSYvIT7"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000019" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_90C_edei--LocalPhoneNumber_c20240523__20240523_zwMQJdZzmj8j"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000020" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--WrittenCommunications_c20240523__20240523_zyRDVc1i4TH4"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SolicitingMaterial_c20240523__20240523_z3OaJ1WawIPc"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20240523__20240523_zvf7FrenH4I7"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20240523__20240523_zNEBEttJp6Sk"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="white-space: nowrap; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b></span></td>
    <td style="white-space: nowrap; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20240523__20240523_zS3XACQWTyub"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20240523__20240523_zIWLgZpzeY78"><ix:nonNumeric contextRef="AsOf2024-05-23" id="Fact000026" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_909_edei--SecurityExchangeName_c20240523__20240523_zGHIIdt79iml"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span id="xdx_904_edei--EntityEmergingGrowthCompany_c20240523__20240523_zbf51xRLn8dk"><ix:nonNumeric contextRef="AsOf2024-05-23" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously reported, over the past year, ABVC
BioPharma, Inc. (the &#8220;<b>Company</b>&#8221;) has entered into three securities purchase agreements with Lind Global Fund II, LP
(&#8220;<b>Lind</b>&#8221;), pursuant to which the Company has issued to Lind: (i) 3,527,778 shares of the Company&#8217;s common stock,
par value $0.001 per share (the &#8220;<b>Common Stock</b>&#8221;) underlying a secured, convertible note pursuant to that certain securities
purchase agreement dated as of February 23, 2023 between the Company and Lind (the &#8220;Lind Transaction&#8221;); (ii) 5,291,667 shares
of Common Stock underlying a common stock purchase warrant pursuant to the Lind Transaction; (iii) 342,857 shares of Common Stock of the
Company underlying a secured, convertible note pursuant to that certain securities purchase agreement dated as of November 17, 2023 between
the Company and Lind (the &#8220;2<sup>nd</sup>&#160;Lind Transaction&#8221;); (iv) 1,000,000 shares of Common Stock underlying a common
stock purchase warrant pursuant to the 2<sup>nd</sup>&#160;Lind Transaction; (v) 285,714 shares of Common Stock of the Company underlying
a secured, convertible note pursuant to that certain securities purchase agreement dated as of January 17, 2024 between the Company and
Lind (the &#8220;3<sup>rd&#160;</sup>Lind Transaction,&#8221; together with the Lind Transaction and 2<sup>nd</sup> Lind Transaction,
the &#8220;Initial Lind Transactions&#8221;) and (vi) 1,000,000 shares of Common Stock underlying a common stock purchase warrant pursuant
to the 3<sup>rd&#160;</sup>Lind Transaction (all of the warrants issued to Lind are hereinafter referred to as the &#8220;Existing Warrants&#8221;
and the shares of Common Stock issuable thereunder, are hereinafter referred to as the &#8220;Existing Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 22, 2024, the Company and Lind entered
into a letter agreement (the &#8220;<b>Agreement</b>&#8221;), pursuant to which Lind will exercise, for cash, 1,000,000 of the Existing
Warrants (the number of warrants so exercised is herein referred to as the &#8220;<b>Outstanding Exercised Warrants</b>&#8221;) to purchase
shares of Common Stock at a reduced exercise price of $0.75 per share. Lind will also receive a new warrant to purchase 1,000,000 shares
Common Stock, exercisable at any time on or after the date of its issuance and until the five-year anniversary thereof, for $1.00 per
share (the &#8220;<b>New Warrant</b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company agreed to register the shares of Common
Stock issuable upon exercise of the New Warrant (the &#8220;New Warrant Shares&#8221;) within 30 calendar days after the closing and have
such registration statement declared effective within 60 calendar days following the closing (such date may be extended if the U.S. Securities
and Exchange Commission issues comments related thereto). Under the Agreement, if the registration statement is not declared effective
on or before the deadline set forth above, the Company shall pay $15,000 per week to Lind until the date the registration statement is
declared effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The New Warrant may be exercised via cashless
exercise in the event a registration statement covering the New Warrant Shares is not available for the resale of such warrant shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Agreement also contains
customary representation and warranties of the Company and Lind, indemnification obligations of the Company, termination provisions, and
other obligations and rights of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the transaction documents
is qualified by reference to the full text of the forms of the documents, which are filed as Exhibits hereto and incorporated herein by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Allele Capital
Partners, LLC (&#8220;<b>Allele</b>&#8221;) together with its executing broker dealer, Wilmington Capital Securities, LLC (together with
its affiliates, &#8220;<b>Wilmington</b>&#8221;), served as the exclusive placement agent (the &#8220;<b>Placement Agent</b>&#8221;) of
the Offering. The Company shall pay them a 2% cash fee on the proceeds received from the exercise of the Outstanding Exercised Warrants.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this Current Report on Form 8-K, nor any
exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does
not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company&#8217;s securities
in any state in which such offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under
the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable
exemption from the registration requirements under the Securities Act and applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained above under Item 1.01,
to the extent applicable, is hereby incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <i>Exhibits.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit <br/>
Number</span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><a href="ea020671501ex10-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020671501ex10-2_abvcbio.htm">Form of Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 23, 2024</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUq37MHHpCKyCInodcsplnRHZjfLT+ovW5VoGBiGe8+9QozEmla6RIbzIs/giFVdKoeQ4w0ZzRW9I91sE/A3x7u2jpVx/fsDU/IMeiYeS3nxQm9ttMUigTCeSDmRMwijZDqHw04EnZ6SuekCjdOqBGUKODDVrNEpboeEo3qToartq07IVpNJIBqHg/wBGUYS9tSoF/HDQpalIhj1E4g107P2ruXboelIWJZY+To70P8NvgZHSow= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea020671501ex10-1_abvcbio.htm
<DESCRIPTION>LETTER AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inducement
Offer to Exercise Existing Warrants to Purchase Common Stock</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Reference
is made to that certain (i) Common Stock Purchase Warrant issued by ABVC Biopharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;)
to Lind Global Fund II LP (the &ldquo;<U>Holder</U>&rdquo;), on February 23, 2023, to initially purchase 5,291,667 shares (529,167 shares
after the </FONT>after the July 2023 <FONT STYLE="background-color: white">1-for-10 reverse stock&nbsp;</FONT>split) <FONT STYLE="font-size: 10pt">of
the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) (the &ldquo;<U>First Warrant</U>&rdquo;),
(ii) Common Stock Purchase Warrant issued by the Company to the Holder, on November 17, 2023, to initially purchase 1,000,000 shares of
Common Stock (the &ldquo;<U>Second Warrant</U>&rdquo;), and (iii) Common Stock Purchase Warrant issued by the Company to the Holder, on
January 17, 2024, to initially purchase 1,000,000 shares of Common Stock (the &ldquo;<U>Third Warrant</U>&rdquo;, and together with the
First Warrant and the Second Warrant, the &ldquo;<U>Existing Warrants</U>&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are pleased to offer to
the Holder the opportunity to receive (i) a new warrant to purchase shares of Common Stock, and (ii) a modification in the current exercise
price (the &ldquo;<U>Exercise Price</U>&rdquo;) of the Existing Warrants in consideration for you exercising for cash a portion of the
Existing Warrants into 1,000,000 shares of Common Stock (the &ldquo;<U>Warrant Purchase Amount</U>&rdquo;). The resale of the Common Stock
underlying the Existing Warrants (the &ldquo;<U>Warrant Shares</U>&rdquo;) has been registered for resale pursuant to the registration
statement on the Company&rsquo;s Registration Statement (the &ldquo;<U>Registration Statement</U>&rdquo;) on Form S-1 (File number 333-276500
under the Securities Act of 1933, as amended (&ldquo;<U>Securities Act</U>&rdquo;)). The Registration Statement is currently effective
and, upon your exercise of your Existing Warrants pursuant to this letter agreement, will be effective for the resale of the Warrant Shares.
Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants (as defined herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company desires to modify
the Exercise Price of the Existing Warrants to $0.75 per share&nbsp;(the &ldquo;<U>New Exercise Price</U>&rdquo;). In consideration for
you exercising the Existing Warrants as provided herein (the &ldquo;<U>Warrant Exercise</U>&rdquo;), the Company hereby offers to issue
to you or your designees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) a new unregistered warrant
to subscribe for Common Stock (&ldquo;<U>New Warrant</U>&rdquo;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended
(&ldquo;<U>Securities Act</U>&rdquo;), to subscribe for up to a number of Common Stock (the &ldquo;<U>New Warrant Shares</U>&rdquo;) equal
to 100% of the number of Warrant Shares issued pursuant to each Warrant Exercise hereunder, which New Warrant shall be substantially in
the forms as set forth in&nbsp;<U>Exhibit A</U> &nbsp;hereto, exercisable at any time on or after the date of its issuance and until the
five year anniversary thereof, for $1.00 per New Warrant Share.&nbsp; &nbsp;&nbsp;For avoidance of doubt, the amount of New Warrant Shares
shall be limited to those Warrant Shares issued pursuant to the exercise made under paragraph (c) herein and not any other future exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The New Warrants certificate(s)
will be delivered within five (5) Trading Days following the date hereof, and such New Warrants, together with any underlying Common Stock
issued upon exercise of the New Warrants, will, unless and until registered, contain customary restrictive legends and other language
typical for an unregistered Common Stock purchase warrant and unregistered shares. Notwithstanding anything herein to the contrary, in
the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo;) set forth in Section 9 of the Existing Warrants (or, if applicable and at the Holder&rsquo;s election,
9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum
number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the
Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through
the Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the amended exercise price), and exercised
pursuant to a Notice of Exercise in the Existing Warrants (provided that no additional exercise price shall be due and payable at such
time, if previously paid at the time of the initial exercise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The Holder will exercise
the Existing Warrants up to the Warrant Purchase Amount upon or promptly following execution of this letter at the New Exercise Price.
The Holder shall first exercise all or a portion of the First Warrant, followed by all or a portion of the Second Warrant, and lastly
all or a portion of the Third Warrant up to the Warrant Purchase Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expressly subject to the paragraph
immediately following this paragraph below, you may accept this offer by executing the signature page of this letter, with such acceptance
constituting your exercise of the Existing Warrants for an aggregate exercise price set forth on your signature page hereto (the &ldquo;<U>Warrant
Exercise Price</U>&rdquo;) up to the Warrant Purchase Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the Company
agrees to the representations, warranties and covenants set forth on&nbsp;<U>Annex A</U>&nbsp;attached hereto. Holder represents and warrants
that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited investor&rdquo;
as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that, when issued, the New Warrants will contain
customary restrictive legends, and neither the New Warrants nor the Common Stock issuable upon exercise of the New Warrants will be registered
under the Securities Act, except as provided in&nbsp;<U>Annex A</U>&nbsp;attached hereto. Also, Holder represents and warrants that it
is acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not limiting
Holder&rsquo;s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act or otherwise
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holder understands that
the New Warrants and the New Warrant Shares are not, and, subject to the registration obligations contained in paragraph d. of Annex A,
may never be, registered under the Securities Act, or the securities laws of any state and, accordingly, each certificate, if any, representing
the New Warrants and the New Warrant Shares shall bear a legend substantially similar to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&ldquo;THIS SECURITY
HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED
OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Holder&rsquo;s exercise
of the New Warrants, certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth above),
(i) while a registration statement covering the resale of such New Warrant Shares is effective under the Securities Act, (ii) following
any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible for sale
under Rule 144 (assuming cashless exercise of the New Warrants), without the requirement for the Company to be in compliance with the
current public information requirement under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions,
(iv)&nbsp;if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then
in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares, or (v) if such legend is not
required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) and the earliest of clauses (i) through (v), the &ldquo;<U>Delegend
Date</U>&rdquo;)). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Delegend Date
if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request of the Holder, which
opinion shall be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date following an event described
in subsections (ii) through (v) of this paragraph, such New Warrant Shares shall be issued free of all legends, provided that, upon request
of the Company (which request shall also include a form of customary representation letter), the Holder has delivered in advance to the
Company a customary representation letter that is reasonably satisfactory to the Company and its counsel. The Company agrees that following
the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than two (2) Trading Days
following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued
with a restrictive legend (such second (2<SUP>nd</SUP>) Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to
be delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request
of the Holder, shall credit the account of the Holder&rsquo;s prime broker with the Depository Trust Company System as directed by the
Holder. &nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Holder&rsquo;s
other available remedies, if the Company fails to issue and deliver (or cause to be delivered) New Warrant Shares as required by the New
Warrant, the Holder shall be entitled to such &ldquo;Buy-In&rdquo; compensation from the Company as may be required in accordance with
the terms of Section 4.2 of the New Warrant.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this offer is accepted
and this letter agreement is executed by you and the Company, then as promptly as possible following the date of this letter agreement&rsquo;s
execution, but in any event no later than 8:00 a.m., Eastern Time, on the Trading Day succeeding the date of this letter agreement&rsquo;s
execution, the Company shall issue a press release disclosing all material terms of the transactions contemplated hereunder and/or file
a Current Report on Form 8-K with the Commission disclosing all material terms of the transactions contemplated hereunder, including this
letter agreement as an exhibit thereto with the Commission within the time required by the Exchange Act. From and after the issuance of
such press release or the filing of such Current Report on Form 8-K, as applicable, the Company represents to you that it shall have publicly
disclosed all material, non-public information delivered to you by the Company, or any of its respective officers, directors, employees,
or agents in connection with the transactions contemplated hereunder. In addition, effective upon the issuance of such press release and/or
the filing of such Current Report on Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents,
warrants and covenants that, upon acceptance of this offer, the Warrant Shares issuable upon your exercise of the Existing Warrants shall
be issued free of any legends or restrictions on resale by Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No later than the Trading
Day following the date of the public disclosure of the transactions hereunder (the &ldquo;<U>Closing Date</U>&rdquo;), the closing (&ldquo;<U>Closing</U>&rdquo;)
shall occur at such location as the parties shall mutually agree. Unless otherwise directed by the Company, settlement of the Warrant
Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall
issue the Warrant Shares registered in the Holder&rsquo;s name and address provided to the Company in writing and released by the Transfer
Agent directly to the account(s) identified by the Holder; upon receipt of such Warrant Shares, the Holder therefor shall make a payment
by wire transfer to the Company). The date of the Closing of the exercise of the Existing Warrants shall be referred to as the &ldquo;<U>Closing
Date.</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, and whenever on or after
the date hereof until six (6) months after the date hereof, the Company enters into an Other Warrant Exercise Agreement relating to Common
Stock warrants and/or preferred investment options issued concurrently with the Existing Warrants, then (i) the Company shall provide
notice thereof to the Holder promptly following the occurrence thereof and (ii) the terms and conditions of this letter agreement shall
be, without any further action by the Holder or the Company, automatically be amended and modified in an economically and legally equivalent
manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in
such Other Warrant Exercise Agreement (including the issuance of additional Warrant Shares), provided that upon written notice to the
Company at any time the Holder may elect not to accept the benefit of any such amended or modified term or condition, in which event the
term or condition contained in this letter agreement shall apply to the Holder as it was in effect immediately prior to such amendment
or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of this paragraph shall
apply similarly and equally to each such Other Warrant Exercise Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">*****</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC Biopharma, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Holder Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIND GLOBAL FUND II LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate Reduced Exercise Price of Holder&rsquo;s
Existing Warrants being exercised contemporaneously with signing this letter agreement: $</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DTC Instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Holder signature page to Inducement Offer]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Annex A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations,</U></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warranties and Covenants of the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC
Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter
period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto
and documents incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC Reports complied
in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i)
under the Securities Act.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter
agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all
necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders
in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms
hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of
the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or
an event that with notice or lapse of time or both would become a default) under, result in the creation of any &nbsp;liens, claims,
security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to
others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material
agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding
to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result
in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the
Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected
to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results
of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
Obligations</U>. Within 30 calendar days after the Closing, the Company shall file a registration statement on Form S-1 (or other appropriate
form if the Company is not then S-1 eligible) providing for the resale of the New Warrant Shares by the holders of the New Warrants (the
&ldquo;<U>Resale Registration Statement</U>&rdquo;). The Company shall use commercially reasonable efforts to cause the Resale Registration
Statement to become effective within 60 calendar days following the Closing Date, which date shall be extended by an additional 30 calendar
days thereafter if the Resale Registration Statement is reviewed by, and receives comments from, the U.S. Securities and Exchange Commission,
provided however that should such date extend to the month of August 2024, the date shall extend to August 19, 2024</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
<FONT STYLE="font-size: 10pt">and to keep the Resale Registration Statement effective at all times until no holder of the New Warrants
owns any New Warrants or New Warrant Shares or until such time as the New Warrant Shares are freely saleable by the Holder under Rule
144 without volume limitations, requirements of current public information, manner of sale or any other restrictions under Rule 144.
In the event that the Resale Registration Statement is not declared effective on or before the deadline in the preceding sentence, the
Company shall pay to $15,000 per week to the Holders (to be allocated pro rata) until the date the Resale Registration Statement is declared
effective.</FONT></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
Market</U>. To the Company&rsquo;s knowledge, the transactions contemplated under this letter agreement comply with all the rules and
regulations of the Nasdaq Capital Market.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required
pursuant to this letter agreement; (ii) application(s) or notice to each applicable Trading Market for the listing of the New Warrants
and New Warrant Shares for trading thereon in the time and manner required thereby, and (iii) the filing of Form D with the Commission
and such filings as are required to be made under applicable state securities laws.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the New Warrant
Shares on such Trading Market and promptly secure the listing of all of the New Warrant Shares on such Trading Market. The Company further
agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application
all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant Shares to be listed or
quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the
listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing
and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock
for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: 28.1pt">(i) From the date
hereof until forty-five (45) days after the Closing Date, neither the Company nor any Subsidiary shall (A) issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B) file any registration statement
or any amendment or supplement to any existing registration statement (other than (x) the Resale Registration Statement referred to herein,
(y) prospectus supplement to the Resale Registration Statement to reflect the transactions contemplated hereby or (z) supplements to an
existing registration statement and the prospectus used in connection with an existing registration statement, which prospectus is to
be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep such registration statement effective
at all times during the respective registration period associated with such existing registration statement). Notwithstanding the foregoing,
this Section (h)(i) shall not apply in respect of an Exempt Issuance. &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a) Common
Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose,
by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, (b) securities issued pursuant to acquisitions or strategic transactions
approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period this Section (h)(i), and provided that any such issuance shall only be to a Person (or to the
equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall
not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities, and (c) securities upon the exercise or exchange of or conversion of any securities exercisable
or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this letter agreement, provided that
such securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with automatic price resets, stock
splits, adjustments or combinations as set forth in such securities) or to extend the term of such securities. &ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind, for purposes of this Section (h)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: 28.1pt">(ii) From the
date hereof until one (1) year following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement
to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock Equivalents (or a combination of units thereof)
involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues
or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional
Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with,
the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities or (B)
with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt
or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company
or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to,
an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities at a future determined price,
regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently
canceled;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that, after one hundred eighty (180) days following the Closing Date, the entry into
and/or issuance of Common Stock in an &ldquo;at the market&rdquo; offering shall not be deemed a Variable Rate Transaction. The Holder
shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to
any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54.7pt; text-align: justify; text-indent: 28.1pt">(iii) From the
date hereof until one (1) year following the Closing Date, upon any proposed issuance by the Company or any of its Subsidiaries of Common
Stock or Common Stock Equivalents or any offering of debt or any other type of financing, or a combination thereof (other than an Exempt
Issuance) (a &ldquo;Subsequent Financing&rdquo;), the Company shall promptly advise the Holder of any such proposed Subsequent Financing
and use commercially reasonable efforts to afford the Holder the right to participate in the proposed Subsequent Financing on the same
terms, conditions and price provided for in the proposed Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="text-align: justify"><U>Form D; Blue Sky Filings</U>. If required, the Company
agrees to timely file a Form D with respect to the New Warrants and New Warrant Shares as required under Regulation D and to provide
a copy thereof, promptly upon request of any Holder. The Company shall take such action as the Company shall reasonably determine is
necessary in order to obtain an exemption for, or to qualify the New Warrants and New Warrant Shares for, sale to the Holder at Closing
under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States and shall provide evidence of such actions
promptly upon request of any Holder.</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses
of the Holder</U>. The Company shall reimburse the Holder $12,500.00 for the expenses of Holder&rsquo;s counsel in connection with its
review and negotiation of the letter agreement, which such amount will be withheld from the Warrant Exercise Price.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF NEW WARRANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea020671501ex10-2_abvcbio.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT HAS NOT BEEN REGISTERED WITH THE
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL
OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">The number
of shares of common stock issuable upon exercise of this warrant may be less than the amounts set forth on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant is issued pursuant to that certain
warrant inducement letter agreement dated May 22, 2024 by and between the Company and the Holder (as defined below) (the &ldquo;<U>Inducement
Agreement</U>&rdquo;). Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in the
Securities Purchase Agreement dated January 17, 2024, by and between the Company and the Holder (as defined below) (the &ldquo;<U>Purchase
Agreement</U>&rdquo;). Receipt of this Warrant by the Holder shall constitute acceptance and agreement to all of the terms contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No. [ &nbsp;&nbsp;]&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ABVC
BIOPHARMA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMON STOCK PURCHASE WARRANT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABVC BioPharma, Inc., a Nevada
corporation (together with any corporation which shall succeed to or assume the obligations of ABVC BioPharma, Inc. hereunder, the &ldquo;<U>Company</U>&rdquo;),
hereby certifies that, for value received, Lind Global Fund II LP, a Delaware limited partnership (the &ldquo;<U>Holder</U>&rdquo;), is
entitled, subject to the terms set forth below, to purchase from the Company at any time during the Exercise Period (as defined in <U>Section
9</U>) up to 1,000,000 fully paid and non-assessable shares of Common Stock (as defined in <U>Section&nbsp;9</U>), at a purchase price
per share equal to the Exercise Price (as defined in <U>Section 9</U>). The number of shares of Common Stock for which this Common Stock
Purchase Warrant (this &ldquo;<U>Warrant</U>&rdquo;) is exercisable and the Exercise Price are subject to adjustment as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <U>DEFINITIONS</U>.
Certain terms are used in this Warrant as specifically defined in <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <U>EXERCISE
OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1. <U>Exercise</U>.
This Warrant may be exercised prior to its expiration pursuant to <U>Section 2.5</U> hereof by the Holder at any time or from time to
time during the Exercise Period, by submitting the form of subscription attached hereto (the &ldquo;<U>Exercise Notice</U>&rdquo;) duly
executed by the Holder, to the Company at its principal office, indicating whether the Holder is electing to purchase a specified number
of shares by paying the Aggregate Exercise Price as provided in <U>Section 2.2</U> or is electing to exercise this Warrant as to a specified
number of shares pursuant to the net exercise provisions of <U>Section 2.3</U>. On or before the first Trading Day following the date
on which the Company has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgement of confirmation
of receipt of the Exercise Notice. Subject to <U>Section 2.4</U>, this Warrant shall be deemed exercised for all purposes as of the close
of business on the day on which the Holder has delivered the Exercise Notice to the Company. The Aggregate Exercise Price, if any, shall
be paid by wire transfer to the Company within five (5) Business Days of the date of exercise and prior to the time the Company issues
the certificates evidencing the shares issuable upon such exercise. In the event this Warrant is not exercised in full, the Company may,
at its expense, require the Holder, after such partial exercise, to promptly return this Warrant to the Company and the Company will forthwith
issue and deliver to or upon the order of the Holder a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder
(upon payment by the Holder of any applicable transfer taxes) may request, calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the
face of this Warrant minus the number of such shares (without giving effect to any adjustment therein) for which this Warrant shall have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2. <U>Payment
of Exercise Price by Wire Transfer</U>. If the Holder elects to purchase a specified number of shares by paying the Aggregate Exercise
Price, the Holder shall pay such amount by wire transfer of immediately available funds to the account designated by the Company in its
acknowledgement of receipt of such Exercise Notice pursuant to <U>Section 2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3. (a)
<U>Net Exercise</U>. If a registration statement covering the shares of Common Stock that are the subject of the Notice of Exercise (the
&ldquo;<U>Unavailable Warrant Shares</U>&rdquo;) is not available for the resale of such Unavailable Warrant Shares to the public or upon
exercise of this Warrant in connection with a Fundamental Transaction, the Holder may elect to exercise this Warrant by receiving shares
of Common Stock equal to the number of shares determined pursuant to the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X = <U>Y (A - B)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.3in">A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.15pt">where,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">X&nbsp;=</TD><TD STYLE="text-align: justify">the number of shares of Common Stock to be issued to Holder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">Y&nbsp;=</TD><TD STYLE="text-align: justify">the number of shares of Common Stock as to which this Warrant
is to be exercised (as indicated on the Exercise Notice);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">A&nbsp;=</TD><TD STYLE="text-align: justify">VWAP for the Trading Day immediately preceding the date of
exercise; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">B&nbsp;=</TD><TD STYLE="text-align: justify">the Exercise Price.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">(b) <U>Intentionally Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) <U>Prohibited Transactions</U>.
For the avoidance of doubt, in accordance with Section 5.9 of the Purchase Agreement, the Company agrees that will not to enter into any
Prohibited Transactions without the Holder&rsquo;s prior written consent while this Warrant remains outstanding and thereafter as provided
in such Section 5.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4. <U>Antitrust
Notification</U>. If the Holder determines, in its sole judgment upon the advice of counsel, that the issuance of any Warrant Shares pursuant
to the terms hereof would be subject to the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &ldquo;<U>HSR
Act</U>&rdquo;), the Company shall file as soon as practicable after the date on which the Company receives notice from the Holder of
the applicability of the HSR Act and a request to so file with the United States Federal Trade Commission and the United States Department
of Justice the notification and report form required to be filed by it pursuant to the HSR Act in connection with such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5. <U>Termination</U>.
This Warrant shall terminate upon the earlier to occur of (i) exercise in full or (ii) the expiration of the Exercise Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <U>REGISTRATION
RIGHTS</U>. The Holder of this Warrant has certain rights to require the Company to register its resale of the Warrant Shares under the
Securities Act and any blue sky or securities laws of any jurisdictions within the United States at the time and in the manner specified
in the in the Letter Agreement dated May 22 2024, by and between the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <U>DELIVERY
OF STOCK CERTIFICATES ON EXERCISE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1. <U>Delivery
of Exercise Shares</U>. As soon as practicable after any exercise of this Warrant and in any event within three (3) Trading Days thereafter
(such date, the &ldquo;<U>Exercise Share Delivery Date</U>&rdquo;), the Company shall, at its expense (including the payment by it of
any applicable issue or stamp taxes), cause to be issued in the name of and delivered to the Holder, or as the Holder may direct, a certificate
or certificates evidencing the number of fully paid and non-assessable shares of Common Stock (which number shall be rounded down to the
nearest whole share in the event any fractional share may otherwise be issuable upon such exercise and the Company shall pay a cash adjustment
to the Holder in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price) to which the Holder
shall be entitled on such exercise, in such denominations as may be requested by the Holder, which certificate or certificates shall be
free of restrictive and trading legends (except for any such legends as may be required under the Securities Act). In lieu of delivering
physical certificates for the shares of Common Stock issuable upon any exercise of this Warrant, provided the Warrant Shares are not restricted
securities and the Company&rsquo;s transfer agent is participating in the Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) Fast Automated
Securities Transfer program or a similar program, upon request of the Holder, the Company shall cause its transfer agent to electronically
transmit such shares of Common Stock issuable upon exercise of this Warrant to the Holder (or its designee), by crediting the account
of the Holder&rsquo;s (or such designee&rsquo;s) broker with DTC through its Deposit Withdrawal Agent Commission system (provided that
the same time periods herein as for stock certificates shall apply) as instructed by the Holder (or its designee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2. <U>Compensation
for Buy-In on Failure to Timely Deliver Exercise Shares</U>. In addition to any other rights available to the Holder, if the Company fails
to cause its transfer agent to transmit to the Holder Exercise Shares pursuant to an exercise on or before the Exercise Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Exercise Shares which
the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (a) pay in cash to the Holder
the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Exercise Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (b) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (a) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3. <U>Charges,
Taxes and Expenses</U>. Issuance of Exercise Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Exercise Shares, all of which taxes and expenses shall be paid by the Company, and
such Exercise Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that in the event Exercise Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto (the &ldquo;<U>Assignment Form</U>&rdquo;) duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>CERTAIN
ADJUSTMENT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1. <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (a) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (b) subdivides outstanding shares of Common Stock into a larger number of shares, (c) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (d) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 5.1</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the beneficial ownership
limitation provided for in <U>Section 10</U>, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the beneficial ownership limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (a) the Company effects any merger or consolidation of the Company
with or into another Person the result of which is the Company is not the surviving entity, (b) the Company effects any sale of all or
substantially all of its assets in one or a series of related transactions, (c) any tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities,
cash or property, or (d) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property (each, a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon the closing of a Fundamental Transaction and payment of the exercise price therefore (including at the election of the Holder
by cashless exercise), the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section 10 on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 10 on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction the result of which is that in excess of 33% of the Company&rsquo;s outstanding equity shall be held by Persons
differing to those immediately prior to such Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction
(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by
paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this
Warrant on the date of the consummation of such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value this
Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the final day of the Exercise Period, (B) an expected volatility equal to the greater of 100% and
the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the
sum of the price per share being offered in cash, if any, plus the value of any non- cash consideration, if any, being offered in such
Fundamental Transaction and (ii) the greater of (x) the last volume weighted average price immediately prior to the public announcement
of such Fundamental Transaction and (y) the last volume weighted average price immediately prior to the consummation of such Fundamental
Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the final day of the Exercise Period. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in
accordance with the provisions of this 5.3 pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <U>Adjustment
to Exercise Price Upon Issuance of Common Stock</U>. If the Company shall, at any time after the Issue Date, issue or sell any shares
of Common Stock (other than in an Exempted Securities), whether directly or indirectly by way of Convertible Securities (&ldquo;<U>Additional
Shares of Common Stock</U>&rdquo;), without consideration or for consideration per share less than the Exercise Price in effect immediately
prior to such issuance or sale, then immediately upon such issuance or sale, the Exercise Price in effect immediately prior to such issuance
or sale shall be reduced (and in no event increased) to an Exercise Price equal to the consideration per share paid for such Additional
Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Calculations</U>.
All calculations under this <U>Section 5</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this <U>Section 5</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding at the close of the Trading
Day on or, if not applicable, most recently preceding, such given date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)  <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 5</U>, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)  <U>Notice
to Allow Exercise by Holder</U>. If (i) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock; (ii) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock; (iii) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights; (iv) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property;
or (v) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company;
then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register
of the Company, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a
record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the
mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. Subject to applicable law,
the Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice. Notwithstanding the foregoing, the delivery of the notice described in this <U>Section 5.6</U> is not intended
to and shall not bestow upon the Holder any voting rights whatsoever with respect to outstanding unexercised Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>NO
IMPAIRMENT</U>. The Company will not, by amendment of the Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in taking all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. Without
limiting the generality of the foregoing, the Company (a) will not increase the par value of any shares of Common Stock receivable on
the exercise of this Warrant above the amount payable therefor on such exercise and (b) will take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of stock on the exercise of
this Warrant from time to time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>NOTICES
OF RECORD DATE</U>. In the event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any
taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any
capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer of
all or substantially all the assets of the Company to or any consolidation or merger of the Company with or into any other Person or any
other Change of Control; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) any
voluntary or involuntary dissolution, liquidation or winding-up of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then, and in each such event, the Company will
mail or cause to be mailed to the Holder a notice specifying (i) the date on which any such record is to be taken for the purpose of such
dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which
any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up is
anticipated to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock shall be entitled to
exchange their shares of Common Stock for securities or other property deliverable on such reorganization, reclassification, recapitalization,
transfer, consolidation, merger, dissolution, liquidation or winding-up. Such notice shall be mailed at least fifteen (15) days prior
to the date specified in such notice on which any such action is to be taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <U>RESERVATION
OF STOCK ISSUABLE ON EXERCISE OF WARRANT; REGULATORY COMPLIANCE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1. <U>Reservation
of Stock Issuable on Exercise of Warrant</U>. The Company shall at all times while this Warrant shall be outstanding, reserve and keep
available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient
to effect the exercise of all or any portion of the Warrant Shares (disregarding for this purpose any and all limitations of any kind
on such exercise). The Company shall, from time to time in accordance with the Delaware General Corporation Law, increase the authorized
number of shares of Common Stock or take other effective action if at any time the unissued number of authorized shares shall not be sufficient
to satisfy the Company&rsquo;s obligations under this <U>Section 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2. <U>Regulatory
Compliance</U>. If any shares of Common Stock to be reserved for the purpose of exercise of the Warrant Shares require registration or
listing with or approval of any Governmental Authority, stock exchange or other regulatory body under any federal or state law or regulation
or otherwise before such shares may be validly issued or delivered upon exercise, the Company shall, at its sole cost and expense, in
good faith and as expeditiously as possible, secure such registration, listing or approval, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <U>DEFINITIONS</U>.
As used herein the following terms, unless the context otherwise requires, have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control
with, the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Aggregate
Exercise Price</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means, in connection with the exercise of this Warrant at any time, an
amount equal to the product obtained by multiplying (i) the Exercise Price times (ii) the number of shares of Common Stock for which this
Warrant is being exercised at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Articles of Incorporation</U>&rdquo;
means the Company&rsquo;s Restated Articles of Incorporation as amended to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than a Saturday, Sunday or any other day on which banks are permitted or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Change of Control</U>&rdquo;
has the meaning set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means (i) the Company&rsquo;s Common Stock, $0.001 par value per share, and (ii) any other securities into which or for which any of the
securities described in clause (i) above have been converted or exchanged pursuant to a plan of recapitalization, reorganization, merger,
sale of assets or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Convertible Securities</U>&rdquo;
means any debt, equity or other securities that are, directly or indirectly, convertible into or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Period</U>&rdquo;
means the period commencing on the Issue Date and ending 11:59 P.M. (New York City time) on the date that is sixty (60) months from the
Issue Date or earlier closing of a Fundamental Transaction (other than a Fundamental Transaction of the type described in clause (d) of
the definition thereof resulting in the conversion into or exchange for another security of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Price</U>&rdquo;
means $1.00 per share, as may be adjusted pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exercise Shares</U>&rdquo;
means the shares of Common Stock for which this Warrant is then being exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fair Market Value</U>&rdquo;
means, with respect to any security or other property, the fair market value of such security or other property as determined by the Board
of Directors, acting in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any
agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the
European Union or the European Central Bank).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issue Date</U>&rdquo;
means May 22, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Person</U></FONT>&rdquo;
<FONT STYLE="font-size: 10pt">means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means, as of any time of determination and with respect to any Person, any United States corporation, partnership, limited liability company
or limited liability partnership, all of the stock (or other equity interest) of every class of which, except directors&rsquo; qualifying
shares (or any equivalent), shall, at such time, be owned by such Person either directly or through Subsidiaries and of which such Person
or a Subsidiary shall have 100% control thereof, except directors&rsquo; qualifying shares. Unless the context otherwise clearly requires,
any reference to a &ldquo;Subsidiary&rdquo; is a reference to a Subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means whichever of the New York Stock Exchange, NYSE: Amex Exchange, or the Nasdaq Stock Market (including the Nasdaq Capital Market),
on which the Common Stock is listed or quoted for trading on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, as of any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of one share of Common Stock trading in the ordinary course of
business on the applicable Trading Price for such date (or the nearest preceding date) on such Trading Market as reported by Bloomberg
Financial L.P.; (b) if the Common Stock is not then listed on a Trading Market and if the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, the volume weighted average price of one share of Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, as reported by Bloomberg Financial L.P.; (c) if the Common Stock is not then listed or quoted
on the OTC Bulletin Board and if prices for the Common Stock is then reported in the &ldquo;Pink Sheets&rdquo; published by the Pink OTC
Markets Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price of one share
of Common Stock so reported, as reported by Bloomberg Financial L.P.; or (d) in all other cases, the Fair Market Value of one share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company (in
each case rounded to four decimal places).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="font-size: 10pt"><U>Warrant
Shares</U></FONT>&rdquo; <FONT STYLE="font-size: 10pt">means collectively the shares of Common Stock of the Company issuable upon exercise
of the Warrant in accordance with its terms, as such number may be adjusted pursuant to the provisions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <U>LIMITATION
ON BENEFICIAL OWNERSHIP</U>. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares
of Common Stock or other securities (together with Common Stock, &ldquo;<U>Equity Interests</U>&rdquo;) upon exercise of this Warrant
to the extent (but only to the extent) that such exercise or receipt would cause the Holder Group to become, directly or indirectly, a
&ldquo;beneficial owner&rdquo; (within the meaning of Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder)
of a number of Equity Interests of a class that is registered under the Exchange Act which exceeds the Maximum Percentage (as defined
below) of the Equity Interests of such class that are outstanding at such time. Any purported delivery of Equity Interests in connection
with the exercise of the Warrant prior to the termination of this restriction in accordance herewith shall be void and have no effect
to the extent (but only to the extent) that such delivery would result in the Holder Group becoming the beneficial owner of more than
the Maximum Percentage of the Equity Interests of a class that is registered under the Exchange Act that is outstanding at such time.
If any delivery of Equity Interests owed to the Holder following exercise of this Warrant is not made, in whole or in part, as a result
of this limitation, the Company&rsquo;s obligation to make such delivery shall not be extinguished and the Company shall deliver such
Equity Interests as promptly as practicable after the Holder gives notice to the Company that such delivery would not result in such limitation
being triggered or upon termination of the restriction in accordance with the terms hereof. To the extent limitations contained in this
<U>Section 10</U> apply, the determination of whether this Warrant is exercisable and of which portion of this Warrant is exercisable
shall be the sole responsibility and in the sole determination of the Holder, and the submission of an Exercise Notice shall be deemed
to constitute the Holder&rsquo;s determination that the issuance of the full number of Warrant Shares requested in the Exercise Notice
is permitted hereunder, and neither the Company nor any Warrant agent shall have any obligation to verify or confirm the accuracy of such
determination. For purposes of this <U>Section 10</U>, (i) the term &ldquo;<U>Maximum Percentage</U>&rdquo; shall mean 4.99%; provided,
that if at any time after the date hereof the Holder Group beneficially owns in excess of 4.99% of any class of Equity Interests in the
Company that is registered under the Exchange Act (excluding any Equity Interests deemed beneficially owned by virtue of this Warrant),
then the Maximum Percentage shall automatically increase to 9.99% so long as the Holder Group owns in excess of 4.99% of such class of
Equity Interests (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon the Holder Group ceasing to own in excess
of 4.99% of such class of Equity Interests); and (ii) the term &ldquo;<U>Holder Group</U>&rdquo; shall mean the Holder plus any other
Person with which the Holder is considered to be part of a group under Section 13 of the Exchange Act or with which the Holder otherwise
files reports under Sections 13 and/or 16 of the Exchange Act. In determining the number of Equity Interests of a particular class outstanding
at any point in time, the Holder may rely on the number of outstanding Equity Interests of such class as reflected in (x) the Company&rsquo;s
most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as the case
may be, (y) a more recent public announcement by the Company or (z) a more recent notice by the Company or its transfer agent to the Holder
setting forth the number of Equity Interests of such class then outstanding. For any reason at any time, upon written or oral request
of the Holder, the Company shall, within one (1) Trading Day of such request, confirm orally and in writing to the Holder the number of
Equity Interests of any class then outstanding. The provisions of this <U>Section 10</U> shall be construed, corrected and implemented
in a manner so as to effectuate the intended beneficial ownership limitation herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <U>REGISTRATION
AND TRANSFER OF WARRANT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1. <U>Registration
of Warrant</U>. The Company shall register and record transfers, exchanges, reissuances and cancellations of this Warrant, upon the records
to be maintained by the Company for that purpose, in the name of the record holder hereof from time to time. The Company may deem and
treat the registered holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall be entitled to rely, and held harmless
in acting or refraining from acting in reliance upon, any notices, instructions or documents it believes in good faith to be from an authorized
representative of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2 <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form of assignment (the &ldquo;<U>Assignment Notice</U>&rdquo;) attached hereto duly executed by the Holder
or its agent or attorney. The Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of the transferred Warrant under the 1933 Act. Upon such surrender, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such Assignment Notice, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the
purchase of Exercise Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3. <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 11.2</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Exercise Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <U>LOSS,
THEFT, DESTRUCTION OR MUTILATION OF WARRANT</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Exercise Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13. <U>REMEDIES</U>.
The Company stipulates that the remedies at law of the Holder in the event of any default or threatened default by the Company in the
performance of or compliance with any of the terms of this Warrant are not and will not be adequate, and that such terms may be specifically
enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of
the terms hereof or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <U>NO
RIGHTS AS A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&rsquo;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for
any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise),
receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Exercise
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15. <U>NOTICES</U>.
All notices, requests, demands and other communications that are required or may be given pursuant to the terms of this Warrant shall
be in writing and shall be deemed delivered (i) on the date of delivery when delivered by hand on a Business Day during normal business
hours or, if delivered on a day that is not a Business Day or after normal business hours, then on the next Business Day, (ii) on the
date of transmission when sent by facsimile transmission or email during normal business hours on a Business Day with telephone confirmation
of receipt or, if transmitted on a day that is not a Business Day or after normal business hours, then on the next Business Day, or (iii)
on the second Business Day after the date of dispatch when sent by a reputable courier service that maintains records of receipt. The
addresses for notice shall be as set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <U>CONSENT
TO AMENDMENTS</U>. Any term of this Warrant may be amended, and the Company may take any action herein prohibited, or compliance therewith
may be waived, only if the Company shall have obtained the written consent (and not without such written consent) to such amendment, action
or waiver from the Holder. No course of dealing between the Company and the Holder nor any delay in exercising any rights hereunder shall
operate as a waiver of any rights of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. <U>MISCELLANEOUS</U>.
In case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal or unenforceable, the
provision shall be enforced to the extent, if any, that it may legally be enforced and the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. If any provision of this Warrant is found to conflict with
the Inducement Agreement, the provisions of this Warrant shall prevail. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH,
AND THE RIGHTS OF THE PARTIES SHALL BE GOVERNED BY, THE INTERNAL LAW OF THE STATE OF NEVADA EXCLUDING CHOICE-OF-LAW PRINCIPLES OF THE
LAW OF SUCH STATE THAT WOULD PERMIT THE APPLICATION OF THE LAWS OF A JURISDICTION OTHER THAN SUCH STATE. The headings in this Warrant
are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its duly authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated as of May 22, 2024&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>ABVC BIOPHARMA, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="text-align: justify"> Uttam Patil</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify"> Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF SUBSCRIPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of Common Stock Purchase Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO:&#9;ABVC BioPharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The undersigned Holder
of the attached Warrant hereby elects to exercise its purchase right under such Warrant to purchase shares of Common Stock of ABVC BioPharma,
Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), as follows (check one or more, as ap<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">plicable):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            exercise the Warrant to purchase __________ shares of Common Stock and to pay the Aggregate
                                            Exercise Price therefor by wire transfer of United States funds to the account of the Company,
                                            which transfer has been made prior to or as of the date of delivery of this Form of Subscription
                                            pursuant to the instructions of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t</FONT>o
                                            exercise the Warrant with respect to ____________ shares of Common Stock pursuant to the
                                            net exercise provisions specified in Section 2.3 of the Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. In
exercising this Warrant, the undersigned Holder hereby confirms and acknowledges that the shares of Common Stock are being acquired solely
for the account of the undersigned and not as a nominee for any other party, and for investment, and that the undersigned shall not offer,
sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities
Act or any state securities laws. The undersigned hereby further confirms and acknowledges that it is an &ldquo;accredited investor&rdquo;,
as that term is defined under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Please
issue a stock certificate or certificates representing the appropriate number of shares of Common Stock in the name of the undersigned
or in such other name(s) as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-bottom: 1.5pt; width: 0.5in"></TD><TD STYLE="padding-bottom: 1.5pt; text-align: justify; width: 0.75in">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 2in">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.75in">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 2in">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">TIN:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%">Dated:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(Signature must conform exactly to name of Holder as specified on the face of the Warrant)</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be signed only on transfer of Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For value received, the undersigned
hereby sells, assigns, and transfers unto ________________ the right represented by the within Warrant to purchase&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;shares
of Common Stock of ABVC BioPharma, Inc., a Nevada corporation, to which the within Warrant relates, and appoints _________________ attorney
to transfer such right on the books of ABVC BioPharma, Inc., with full power of substitution in the premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">[insert name of Holder]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">[insert address of Holder]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify">Signed in the presence of:</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>abvc-20240522.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qA5s7xRiXgen8uKa3EsWa+IWaPtzplyCZlBtmd5bbmq7yotqhId6yv5s9lG8VQA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ABVC="http://abvcpharma.com/20240522" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20240522">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240522_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240522_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>abvc-20240522_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>abvc-20240522_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20240522.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139882065321312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 23, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 23,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M+6M^N.(,YH)] .XOI#2'$[MO+?[M,/@/4$L#!!0    (  :(MUB?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    (  :(MU@'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !HBW6-62
M"W/O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ !HBW6)E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  &B+=8M]PX3T\$  ""
M$   &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ !HBW6)^@&_"Q @  X@P   T              ( !DPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  &B+=8EXJ[',     3 @  "P
M            @ %O#P  7W)E;',O+G)E;'-02P$"% ,4    "  &B+=8JL0B
M%C,!   B @  #P              @ %8$   >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ !HBW6"0>FZ*M    ^ $  !H              ( !N!$  'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ !HBW6&60>9(9
M 0  SP,  !,              ( !G1(  %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0206715-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvc-20240522.xsd</File>
    <File>abvc-20240522_lab.xml</File>
    <File>abvc-20240522_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0206715-8k_abvcbio.htm">ea0206715-8k_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0206715-8k_abvcbio.htm": {
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20240522",
   "dts": {
    "schema": {
     "local": [
      "abvc-20240522.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20240522_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20240522_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0206715-8k_abvcbio.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://abvcpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-05-23",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0206715-8k_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-05-23",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0206715-8k_abvcbio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-24-046313-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-046313-xbrl.zip
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M@IH\),7SX#V4@'JWL/38;C(#B -"I]LA0) ,0LTHGR#-6<3%,Z\][C#C6SD
M[F<\AE<H/5%NH1K4A"9:G2$! 3;$)X!9(_1#\4P*XNH]GKP"I&KP0MQ%',L#
ME9;_7">,'(/MMVK=TM5AM\F411@02; [@)]2^4%_0"H&W;)0H)F^H:E3_]!,
MAT(S#1J:Z7N@6;[R0* Y>4-33_Q#<S(4FI.@H3EY%S2RX[V.-3/Y\58L^:OM
MX6Q0Z069ME4K, =9>+BTO/7!H@+4>D:%^,0D7UC=BCO!7Q(6P4MF2.X%&,"T
ME1I#&QXZ=H-]_%0+8AWG=:PI%N6]7Q(M\S/*-$W:AYA"$QXD36.]@TNA]HG$
M'4\S3/^=/'>>B-O%7O"P&K9"TE"&AXK-7A\P10R203Y.K$M<U0T-ZZMD1KF[
M5X MM@ZO -<*@X# YJC]"G!Q]:00N>YFQ:@@&!@1FL7..MEBJNKC6ED87=PV
MU.KA_'LM-3Z^R"J["[U[Y Q^0* M<=73D#G=VV9Y$#T.F#)[/9>A7.?I:KS*
M,)':A^]:F;.9W;133>2Z((C>-=VTIFE=[K@W?Q-))O<\XYO-EI5W>6S/#0(Z
M5[W<:5/WN%441.]W.3-)*+6H*7:,Q8+3)$JRA*U_D2>?(L&V5ME$KH" #6H:
MVHH@4 !MF1P<A$@K'4-P)XB"D,B.R%\"5(F%Q.W#@W6V[Q*[@J+?L(8#5@8!
M2:\]$Q89,(YJ$:@(07F,7VSF:;HEXDWP6$(\(02:!T!JZ4/$"3+9"U41Z).M
M!8FV<G[<'T]7RR2CMI/+ML39G 28JV8DHSP(-@!3)@MY&>(/Z'CZU]7?D(YR
MW/TW?"FP2AZ[V&]6G +9IZPJ5Q!T6-0<6"1!H #[,FFXX:B4HD+K(SM5PZRE
M.4:Y*P"LMG37-PJ#Z'2;H]:7O]'7GH;\RUWT*$T1X(4$N\SUT&\S:0[_=4T0
M"'08:YV4E%*DM3Y>2#A,6>O^1<#:VR)@W;,(6(>X"%@/702LO2T"]&Z+%"%R
M7+I=T62-@>2$G6K74'18-OFP2(-"!?8'CAE5"#K$N,YHF:<X4^GYQ2;?_Y7\
M8&DEH'.6T[++9I74TB8*@I$N9ZVTED72N9H8*;5K+K9QDI&X,'.5,,RB!-,J
M/:+MBGA_B#-:!IJOP.G1A\'0,),MG(HPG<NP"CRDNG1]*;UX .,W0NG/C+^R
M!<$I9R0NKJ78[A1UZ]T^,=-CN_G0#" . J<A#H%'9U30^$E%(1U67@GS0M(W
M3K<LPR)_EUS81B9 YY8<P&:3&$,4$"EV9P AE1@5:C\O:!?9(ZI%5O&[0V #
M(;GCU[4[31MO;5NU 3'3:1!ZA[O,^7%8&Q=1GEZQS(CZO8CDA7S!&2Z]@>V%
MY*Y?JNPR;;Y-:=,&A%"G0?#]R2I&I8K!FBEO*6/$3"ZUUKSC*7%#Y3YQ3,MB
M.W=,)0D(#YNOC@PR FFM%Q86&TSIYVV:,)+"$Y&A<LN"U6*3A88D(!9LO@ 6
M<BG26B\L7&Z(6,OI[2?!7[/',C\KV#9 [9:-3LM-1JS2@%CI\@<PHT-0$:-3
MZOJ!9W=(*%YD681;:I$ZQ@8T:S#3TH4$#&2N10LED;K><L,SM.3H:TI0]DC0
M9?DS=/5,\$4]OGYI)(K4"Q'%JIS%6-@0ZA([_]41T'#KMT=:RB! ZK4'_PY)
M%8%TB&-J;B7#HGX>EYN89V0#ONW0'^**H*'F-4=]^B!H&FC29"H/:YY<YX%(
M1?K,9E1/;@\O\1HBQRMCBT%C85Q3!,$(: M:%M=_*\!/[KSMBB;1%>48OLK2
MT#C.F->V9R3+.P@"(J#M"DJ1EPM1KO32_Y\Q>Q+;YRS:WPD>$:*>LDJKT:KO
M^MO :+?,O*E)39H&A0;$V5O\ @0>JD"U.C[49BR?%_/40^,JFQN/GA:/6![
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ML'C]=&-Y[4_YIPIL,"]FZGQC6_7>);"RK":R^NS9LXV=[U^^V-H2L&AZ4!=
MG. \!E&%0-Q^]0Q(+VPVA+$GL,F>1TF=I]UYY2Q6; -D#<%7(($Q7)^H@HL!
M7#:;!*J>P[. 7H7!95P&?;!\7CZ88=PTKI QAY=%3',%0 +3%$[*SD/'5"UA
MBG_6F\!#PGE2 4GX':]Y7,Q*E>4 $J2K-[BJ23Q-,O@._H[AC@ :PT17(4R
MP\WB,(.EEJJ,*YP1Z+!<521)%N$ LOY _<UOBZ".' 8ZB<L$:0&<)A&Y!=-4
MGVJMIE3P&D@YW[^P0@YOJW%M< NK">$FB*W+!*_;:5"\]A7 :<Z+_#J96+Q8
M05+T GSYPY4F\'T0,(B]T-Y(Z""Q&-?"1+@@F%UF<5R^OK?3XY_+RJ51:QX.
M6WJA9IYUYE!>X:0$G+(>EU&1C/FB^SS%1X(6$="C*.=(,.#EYS!K;\>PR+N)
M)$C"ZU!)$@;]Y=9S_"S45/H.INALHHU'Q;_584HP0:.$7KX=VG]5"[4N!.(P
MNE)-E"7,))X1H%(#3[CK8#H(V\&-5? )2[I)QG<9-CFC>^+21<&G"V/E&N ^
M%'^,LU5YH"]?. ::':(("U(5X!2R. "<5<@FP&9P=TG%6PI!OR7Q"<2%)&6A
M9(I\8!&#<A1F68)Z& KI2-KC?!K027RW#?H249(E*&_RPF1]_/,=KN$Z3R8T
M'4P_R>NQ2-0AB2KXX?*!@3"@ 98F,] 0)\S+\K+)DMK.!T<W;)+T=^;EH/8!
M"PSG5ZH7]34E0A@@"T/($1M3T[JJ"SO"-\9Y>N,^22D>0T:[!TO7<:_L=SM:
M?)C$*>()TAK0J0":A$*]%S!$$4Z0"1R$BQ(P)TWS&\T@"!4U4B'XR]J_+670
MT-7P;!PIU1=?!0%(0G*%HZ94P4(/B%)9&I>E@_N68@;(XLC $P&( *J _H!C
M%7!#DI'2^!(H&;_+N)*&V64=7B(#6LS1GDFW),Q\0NQ1*Z/4W#AJI_<XR_Z;
MH.U7N'VD%P1+  ,"^5*CKJ ZKKF I0:&G,37*%"2Q0I!MT2J;O(ZG3A"6Q36
M9>QHZ43D/D5QS/KP.,Y &(N 9*G\)@.R<)7,^5Z2)%"Z'&3//-OMG)B'C\S#
M'BGVI$#-5UZM%F5Z.1#79*K"^3P%8!/- ^"%E;-VHRW$*0\8=#NO-E^]^N^&
M(,$$)L^0"B,&,1:N9 .>%8-!RU!$VG$'_&;AIV16S[J=E:,#004 5?R\82,H
M!8/D%U76J**M*-J$H<9A2K059ASCK8(5(5$;QPOZF#$<UH@BXK3(9TSIW6VX
MHP" C:HJ=+\/RU_@V'+/2/&= ?SI!5H'0<[!!\T S2H,,8]1"(1/<)]%7E]>
M:5&V>=(\@'EO@GH+$/DBGH>) (EY6R_)HK2>:-HR#Q>L3 $IJO%\I\)K6$TS
M]('L &+:TA^"@.)RD1#OGTC6YN:(MM*"FD;"):!F\/YDDB XX-;XTSK;JAF!
M8=6:@2,L 2A R@G38<?725Z7:!7#G<MY,8OGO8G=S$SRK:E*R,M']NH1:[(&
MG_;38H'257 ;%A1F)W@;X,[,42.W/ P&CVIKS7'TZ\HP'5^3 KW962$?_Y1,
MCP8SB!@52Y8BY5DH UD%TX-5KS3-EXAA:5C")KJ=5>]XEM.[P?.-H9B9\[\V
M-N!$@,B^5J? ]=_ P+_52-!@?K6Q(4[TMP>'/^G%N4[2[9T6+^E+_&R<%X 9
MYK.]- 1!87OS!:RSS--D DLX]4>D3;@P>?L49FU9P!@HY<>-<0Q\%E8YIU6[
MBWK9LB9<Z.=.Z8#F*<*&P?&M8,CP$U#J$LDT*'B_ LO6%\CH'""HSH"')2#\
M>M2$"(C53,8Q?!Z0+0/Y;AA%\;SBA]BD#A=?")"P/#1TA*2QX.$V:%+@<&@>
M*R3')IIRJJ3B49;LBNU$4R3;\/(29%64X9MLS4ASVE;96!KKK"ML/V@37VF&
M?VB"])"H-3!R1+KP1%B@YFC0+:TU'7$07C52&,,*;2S( Z(<U (Z2?>DC)5A
MD&7Q)[8Q\&=A5871E=CLJGQ3\R\S#P\KLY3(:\.*I%9!(4?14PD:N)D7H9Z&
M%A0V260BZR66&9:DM7@**'PK.B>.H;$',!KT)3(/)-DU*&IY(2@#L+$F9!#:
MSFH0KUYL;>/2SN++.F4;Y@'Q]SI%=)ZH519_7K8&-FWRYBK.1"(.ENW7M%11
M)>&NW:9+\MA9G) ZN312)E9Y3X,D^PW*BW?JO,;.;[7+U8Z-@'06P$[77IM\
M#H(,TC(/[D 3EH^3BH(KPNBW.BDT)?-63HL X3Z9BU*-EBM0/Y&,D82&@Z*_
M"41MUI)0L(&[P[_3,)?B3BKX:+4B75JK NG (/?#EZC(5C@6GM&X1MS$35R&
MA=$NS'>.Y.0M.E\Z0JWA]8@H^U<473ZH/I+J!'-HO<RHL!3H1N;0.$U7C>SI
M+)GCT7&]:\HZUU;[M0IK$H#36=;S'+5[&J,?(&7S#0X-2S2#I>%-^:UI(8Y\
M;W&-D9V5$!^Y)=*@Y3C1CPY(070A:$H3WI'F8UB76&"$V#"QL]+$9!/15"YN
MT.V@2)%AA T14L?DM)HF"$HWCA>')2L*G3TM%>\E715D4T3@':LAFVVR16"O
M "'\YT!&J\UHGQ;RV3"GEW"1TK#0T#)"UOTY@>X=Q<2KM+/*K;0"SYG_C=X?
MGJOSX?[%V>'H%Z >@W-U?#)2>\/AL3H;_GAX/AJ>#0_4SX>C]VKT?J@?/1R>
MJ\'Q@1K^>__]X/C'H=H_^?#A\/S\\.18G9PUGW2_? ?O80SP8#14ASC'T>'@
M>'^H+D[AV\$QC#C\<#J"1[N==V<G'V019P/\2%T<'PR71A_LCW!8]A7!^@<?
MAO#8@>KA<[)-_W'K)X(]P(_]_9,S#&H]^B50'P:_" 1@T'>X^6X'=G1^<D2[
M'9Z.U.G%V?G%X'BD1B>T8GAL?W3XT]!?*VT1EC*Z9=5GS;$&/PT.CRC6UL!!
M(1@">+;; 7@-%(Q_? YOXU>XT/.+O7_!_#! 0'-XBS@;_M^+PS-:QCD"J641
M>(PX, &!CH(.>W!Z>G2X3TOAP[*O=3M'@Y_/-P6*WQ:1OIA+9$G35&S,1:U^
M X>.E=J$V2*S^'2*[,+B34!**02K8:_49,P(Y.$8I'2.&NRC9(Q6P56<' 5Z
M(SS9N(VF.\5ZRASA8#7!IW@J0SHQ_@0(ZQU#NS((B=K;SY_?/@7,D:P>#YE@
M# >:D*P!+ @7H"57,T$O!$%XA@# *"ORZMPF#/=9&<[K2@"&LB=#<FK%;!VS
M.([;3-UD/==A9?,:.' $CZ'[E@_'';2QVK!DQ_:*'6<3L[KK/*UG)'X"[F=Q
ML9%/-^@$C/Z ZAVBR'6?+],MH!3K?0D8WUS1Y\+/,&<-I@0%G#AK%1;=^+M[
M!!0))+UKBSUR@UB4[G9D7+U71V1U9BQ7!"TXE_-7^(<\7@FF?H#(HGU=9*\O
M\@QTD$@&\^->X7Y.IX:2.#/@F\-/T17J):30P7OM4=_RC6<"T; '\2>%T<AQ
M'J7H>"HI>%(<*@B;9L3J0<Q ZG8.@'2T1*3Y/C'V9J&ZA8H6J!XFS(;E+G0#
MSI.,?$0L:(W@@$HT3@TNZ;BUS=R&'^@E*%P!X,M4F8-JA O#/I_*;6P,BTXU
MHE]R?6?Y=6@\/#*\XSW+C4$>IQ*(>3XTM#O 0<E>C%<FH=BFF;BF2;Z,<) 0
M5$3 )&V4(Z3RW(*;ZAUZV,A8T+YSQ^Z'JAJY:2<Q1[I,Z!KAA.RW+)D2.^=J
M;'M&P ]67GN[&T;.:1'3I<9/C>G!\UE)D*$ RR"P/I<>FVDT+'G\$!1^Q9<&
MD8/ AGCI6#P\A9>-DH*@HBY=D:5&QQ$@MYQ<:Y<FD5N#&7>-*Z:%TCVK$AXH
MIV%4Y84)17=0S45S_RXXYAZ7&RX?*>,9G0.YY3"*ITF85)K#I2]4@SK188K?
M.] VKH">#V4_<,=N<H5Q5FY$1;?3"*E@^"U\-W%SO^W7"I'"%7$\#6V5C,-8
MA8$@*+.T&+94CX!0LB^JM_/V_.)T-YN\?8K_>IMI4JLC?O],[G>39 5ZLXJB
MJ\GQGG<[7C"*[ZR_97>\1O'P"_+032%7.6*XNS,G[$,"03 >P2<RYMYH*B,T
ME>R4[(L6^Y7WG!%%YP7BT+C(/SJ)"H!Q\[Q,"(='!5P"<Z3G"U#@9RV1 MJ6
MM.G%8WU;XOXZ;KN=-^ID3N3V-2Y +N,;]1.F!\'77\NKMYQNNE:"Y;TF%SI@
MT@!ZHT:+.3PQ*,)Q$KU1Q^$L9B >YPB:'<_OI]_";YP\F$?7Y$/>@L/,A*+X
MA%'3'"!91-3"ZS!)151&3R7.G?A"P!2>*!UQ$ BBIL8]AQQ[H8']5G6G7!(
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M!!)?<R!H6#<\2L.$^((4?5UP$;2X1)5(B%T&VQL7K$ODV&]O2GH7)W9:H0&
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MQI%0DIRA>T3*R#9,MA3=C:]E-LS=U3 DBRN)2[80B123>=D\,C^)UD^[9XY
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MUR:-[)<(BZF'B49,O-4-TB1=E;A@'=W;N$FJV@=6MX[K0UYBB73?Y*7J]D1
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M.!UN?GF5S .X8+#FP,\?IZ@H[Q,MVM#[OX)@4BF,**H+]/E(5E2:Z!!A(4/
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M> >VY&%9>, %F?AX$AHH7R7]*M$-WKDI,KN,E&84>\3,*E+1V78*PZ&X0^Q
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M44B@&.81+:@*X"PR'J.2BCX-<R +9P!<<+EU)^03:,49ZUM?6$E*=DTGMZV
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M  5\CLVK:MDV.F,;^'.UTX6Z7+E<2/MF1 HS;>VJW7*6-]CWY*BY&#<L.MO
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M=_3Z_P-02P$"% ,4    "  &B+=8 7V#MBT#  #I"P  $0
M@ $     86)V8RTR,#(T,#4R,BYX<V102P$"% ,4    "  &B+=8+1,-B?T*
M  " A@  %0              @ %< P  86)V8RTR,#(T,#4R,E]L86(N>&UL
M4$L! A0#%     @ !HBW6+1+;FA9!P  V5<  !4              ( !C X
M &%B=F,M,C R-# U,C)?<')E+GAM;%!+ 0(4 Q0    (  :(MUA-TI>?@!<
M +6    8              "  1@6  !E83 R,#8W,34M.&M?86)V8V)I;RYH
M=&U02P$"% ,4    "  &B+=8\X  D%<K  !6T0  '0              @ '.
M+0  96$P,C V-S$U,#%E>#$P+3%?86)V8V)I;RYH=&U02P$"% ,4    "  &
MB+=88M_+DC-&  !,9P$ '0              @ %@60  96$P,C V-S$U,#%E
G>#$P+3)?86)V8V)I;RYH=&U02P4&      8 !@"A 0  SI\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ea0206715-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20240522.xsd" xlink:type="simple"/>
    <context id="AsOf2024-05-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-05-23</startDate>
            <endDate>2024-05-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-05-23" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-05-23" id="Fact000004">0001173313</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-05-23" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-05-23" id="Fact000010">2024-05-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-05-23" id="Fact000011">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-05-23" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-05-23" id="Fact000013">001-40700</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-05-23" id="Fact000014">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-05-23" id="Fact000015">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-05-23" id="Fact000016">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-05-23" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-05-23" id="Fact000018">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-05-23" id="Fact000019">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-05-23" id="Fact000020">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-05-23" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-05-23" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-05-23" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-05-23" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-05-23" id="Fact000025">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-05-23" id="Fact000026">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-05-23" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-05-23" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
